Advanced Cell Technology Completing Pre-Clinical Activities in Preparation for IND Filing
9/22/2009 11:03:23 AM
WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC) provided an update on pre-clinical activities in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases. In the next few weeks, the Company will be completing the preclinical work necessary for filing the IND. To date, no adverse events have occurred in testing. The results will be part of the submission which Advanced Cell expects to submit to the FDA prior to the end of the year.